We Give Shareholders a Voice
Levi & Korsinsky announces the filing of a class action lawsuit in the USDC for the Eastern District of North Carolina on behalf of shareholders of TransEnterix, Inc. (NYSE MKT: TRXC) who purchased shares between February 10, 2016 and May 10, 2016.
TransEnterix developed The SurgiBot ™ System, a surgical platform designed to be minimally invasive and allow for multiple instruments to be introduced and deployed through an incision. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that (a) there were deficiencies within the Company’s 510(k) application to the Food and Drug Administration which undermined the likelihood that the SurgiBot would receive FDA clearance; (b) that as a result of these deficiencies, TransEnterix would be unable to commercialize the SurgiBot in 2016; and (c) consequently, the Company’s ability to obtain approval for and commercialize its other robotic surgery platforms in the U.S. would be impaired.
If you suffered a loss in TransEnterix you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.